News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 673 results
November 2019
-
Media ReleaseNew Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell diseaseSickle cell pain crises are unpredictable, severe events associated with life-threatening complications(1)Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63…
-
Media ReleaseNew Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
-
Media ReleaseNovartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace- PsO at Work provides a critical resource to help the more than 8 million Americans with psoriasis balance the demands of their jobs with managing their symptoms(1)- Lauper will highlight her PsO at…
-
Media ReleaseNovartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace
October 2019
-
Media ReleaseNovartis STEP Program™ now accepting submissions for proposals that address unmet patient needs in cancer biomarker testing- STEP Program is available to US-based nonprofit patient advocacy organizations- Recipients will receive funding to support proposals that demonstrate innovation in awareness and education, self-…
-
Media ReleaseNovartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs afliberceptIn two head-to-head clinical trials, patients on BEOVU (brolucizumab-dbll) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of…
-
Media ReleaseNovartis STEP Program™ now accepting submissions for proposals that address unmet patient needs in cancer biomarker testing
-
Media ReleaseNovartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
-
Media ReleaseNovartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum- Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)(1)- Novartis plans FDA submission…
-
Media ReleaseNovartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
Pagination
- ‹ Previous page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- …
- 57
- › Next page